In this study, we made use of a newly developed comprehensive in vitro drug-testing platform to prioritize putative drugs, including histone deacetylase (HDAC) inhibitors, for their implementation into a new clinical trial for patients with metastatic HB. This evidence concerns the gene HDAC9 and hemoglobin measurement.